• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

With just a lit­tle en­cour­age­ment, biotech in­vestors are ready to fall in love again

8 years ago
People
R&D

Scott Got­tlieb likes his job run­ning the FDA, but he is­n't rul­ing out a big HHS pro­mo­tion

8 years ago
Pharma

In­dia’s Lupin bags Sym­bio­mix and its new­ly ap­proved an­tibi­ot­ic for $150M-plus

8 years ago
Deals

Deer­field com­mits $50M-plus to trans­la­tion­al drug R&D at the Broad

8 years ago
Financing

Am­gen catch­es a break as FDA re­jects Neu­las­ta knock­off; Zaf­gen gets a new CEO as Hugh­es moves to top sci­ence job

8 years ago
News Briefing

Gi­ant Mer­ck bud­dies up with lit­tle KalVista on lead drug, ig­nit­ing stock with a $760M deal

8 years ago
Pharma

Ab­b­Vie jumps on the on­colyt­ics band­wag­on, em­brac­ing Turn­stone in new col­lab­o­ra­tion

8 years ago
R&D
Pharma

Eli Lil­ly con­cedes a PhI­II flop for abe­maci­clib as break­out strat­e­gy floun­ders

8 years ago
R&D

Spark Ther­a­peu­tics faces a grilling as FDA pon­ders a pi­o­neer­ing OK for gene ther­a­py

8 years ago
Pharma
Cell/Gene Tx

Ab­bas Hus­sain swings from top GSK phar­ma post to pow­er­house Chi­nese pri­vate eq­ui­ty play­er C-Bridge

8 years ago
People
Financing

Biotech sci­en­tist/en­tre­pre­neur Saurabh Sa­ha makes an un­usu­al re­turn to the arms of a big — and ex­ces­sive­ly dis­creet ...

8 years ago
People
R&D

Third Rock-backed Al­lena looks to spring­board a $92M IPO off of a failed PhI­Ib

8 years ago
Financing

Flex­ion nabs FDA OK for its po­ten­tial block­buster os­teoarthri­tis drug, trig­ger­ing new buy­out buzz

8 years ago
Pharma

As­traZeneca’s next big can­cer drug linked to fal­si­fied pre­clin­i­cal da­ta; Har­mo­ny rais­es $270M, nabs de­vel­op­ment ...

8 years ago
News Briefing

David Meek­er starts a new biotech chap­ter in his ca­reer; Sam Kulka­rni takes the helm at CRISPR

8 years ago
Peer Review

Third Rock, SV bankroll an­oth­er PhI/II for a new, im­proved and jab-free wet AMD drug

8 years ago
Financing

'Go­ing big': Mer­ck launch­es front­line PhI­II lung can­cer study for Keytru­da/Yer­voy com­bo

8 years ago
R&D

Fac­ing an ex­o­dus, EMA starts to line up temp re­place­ments as top staffers jump ship

8 years ago
Pharma

In a set­back, Bay­er, J&J say their big PhI­II sec­ondary stroke tri­al for Xarel­to failed

8 years ago
R&D

Al­ler­gan shows how you can de­stroy your rep and get mobbed by law­mak­ers in 4 easy steps

8 years ago
Bioregnum
Opinion

We've tak­en a big step for­ward at End­points News — and with your help, we'll make more strides

8 years ago
Editor's note

Sanofi/Re­gen­eron win a new tri­al on Pralu­ent patents; Bridge­Bio bankrolls $30M biotech start­up

8 years ago
News Briefing

Aca­dia adopts a new PhI­II game plan for 'break­through' med, dumps Alzheimer's PhII

8 years ago
R&D

Face­book bil­lion­aires Pe­ter Thiel and Sean Park­er back­ing a stealth im­munother­a­py biotech — re­port

8 years ago
Financing
Startups
First page Previous page 1078107910801081108210831084 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.